| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| sulfatinib | macrophage colony-stimulating factor 1 receptor | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.21 | phase 3 | unknown |
| sulfatinib | fibroblast growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.42 | phase 3 | inhibitor |
| sulfatinib | fibroblast growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.42 | phase 3 | unknown |
| sulfatinib | vascular endothelial growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.3 | phase 3 | unknown |
| sulfatinib | vascular endothelial growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.3 | phase 3 | inhibitor |
| sulfatinib | vascular endothelial growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.29 | phase 3 | unknown |
| sulfatinib | vascular endothelial growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.29 | phase 3 | inhibitor |
| sulfatinib | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.28 | phase 3 | unknown |
| sulfatinib | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Carcinoma Neuroendocrine[MeSHID:D018278] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.28 | phase 3 | inhibitor |
| click here to return to the previous page | ||||||||